Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Stomach interference in 82Rb-PET myocardial perfusion imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rubidium-82 PET imaging is feasible in a rat myocardial infarction model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Doxorubicin is the mainstay of curative lymphoma treatment but is associated with a dose-dependent cardiotoxicity that is often recognized too late to avoid substantial irreversible cardiac injury. Iodine-123 metaiodobenzylguanidine (123I-MIBG) is a gamma-emitting tracer that mimics noradrenaline uptake, storage, and release mechanisms in adrenergic presynaptic neurons. 123I-MIBG scintigraphy can be used for assessment of doxorubicin-induced injury to myocardial adrenergic neurons during treatment and could be the tool for early detection of doxorubicin cardiotoxicity, which is currently lacking.

METHODS AND RESULTS: A total of 37 lymphoma patients scheduled for doxorubicin treatment were included in our study. 123I-MIBG imaging was performed prior to chemotherapy and after a median of 4 cycles of doxorubicin. Early and late heart-to-mediastinum ratios (H/Mearly and H/Mlate) and washout rate (WOR) were used for evaluation of cardiotoxicity. The prognostic value of 123I-MIBG results was assessed using left ventricular ejection fraction (LVEF) as measured by cardiac magnetic resonance at 1-year follow-up. We found a post-therapy increase in WOR (including nine patients with > 10% increase), which was not statistically significant (18.6 vs 23.4%, P = 0.09). The difference appeared to be driven by an increase in H/Mearly. LVEF decreased from baseline to 1-year follow-up (64 vs 58%, P = 0.03). LVEF change was not associated with changes in WOR (P = 0.5).

CONCLUSION: The present study does not provide evidence for 123I-MIBG imaging as a clinically applicable tool for early detection of doxorubicin-induced cardiotoxicity.

OriginalsprogEngelsk
TidsskriftJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Vol/bind27
Udgave nummer3
Sider (fra-til)931-939
Antal sider9
ISSN1071-3581
DOI
StatusUdgivet - jun. 2020

ID: 56242040